Biofourmis, a digital therapeutics startup that employs wearable devices and data analytics to help treat patients, has raised $100 million to scale its offerings globally and develop new products that further blur the lines that once clearly separated drugs from medical devices.
The new capital, a Series C round of funding, was led by SoftBank, a Japanese conglomerate whose investments include companies working in digital technology and healthcare.
Biofourmis’s flagship technology, BiovitalsHF, is prescription software designed to detect the early signs of heart failure. The FDA-cleared product includes a sensor worn on the arm and a companion mobile app that together... Read more »
UNDERWRITERS AND PARTNERS
Author: Frank Vinluan
Date : 2020-09-03T15:29:26.000Z